Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

To investigate the multimodality approaches for mHSPC

Inclusion criteria

• Male aged ≥18 and ≤75;
• Histologically confirmed prostate adenocarcinoma;
• Evidence of metastasis confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histology;
• Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis);
• Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.);
• The surgeon believes the prostate can be removed;

Exclusion criteria

• The surgeon believes the disease is unresectable;
• Life expectancy less than 2 years;
• Active spinal cord compression;
• History of prior local treatment for prostate cancer;
• Difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption;
• Refusal to sign the informed consent;
• Investigator believes the individual is not suitable for inclusion.